Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial

Rahman, Md. Mushfiqur; Dondorp, Arjen M.; Day, Nicholas P. J.; Lindegårdh, Niklas; Imwong, Mallika; Faiz, MA; Bangali, A Mannan; Kamal, A.; Karim, Jahirul; Kaewkungwal, Jaranit; Singhasivanon, Pratap

doi:10.1016/j.trstmh.2008.05.022

Cited by 52 publications

(73 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Out of the 1,813 potential articles, 16 fulfilled the inclusion criteria ( Figure 1) [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] and comprised a total of 9,247 patients. Of these, two studies included two different interventions.…”

Section: Resultsmentioning

confidence: 99%

“…Ten studies (62.5%) were undertaken in Africa [20][21][22][23][24][25][26]29,31,32 and the remainder were set in Asia. [17][18][19]27,28,30 All the studies were based in the public healthcare sectors (12 in a hospital 17,19 -22,24 -31 and 4 in a community setting) 18,23,25,32 but one study also included a group from the private sector. 32 Eight studies (50.0%) investigated the impact of adherence promoting intervention on children or their mothers/ caregivers.…”

Section: Resultsmentioning

confidence: 99%

“…20,22,23,25,26,29,31,32 The other studies enrolled adults or patients at all ages. [17][18][19]21,24,27,28,30 In 14 studies (87.5%), the patients were infected with falciparum malaria [18][19][20][21][22][23][24][25][26][27][28][29]31,32 and the remaining studies used patients with vivax malaria. 17,30 Six studies (37.5%) used chloroquine, [20][21][22][23][24][25] five studies (31.2%) used artemisinin-based combination therapy (ACT).…”

Section: Resultsmentioning

confidence: 99%

“…17,30 Six studies (37.5%) used chloroquine, [20][21][22][23][24][25] five studies (31.2%) used artemisinin-based combination therapy (ACT). 26,28,29,31,32 Other antimalarials were artemisinin monotherapy, 19 sulphadoxine-pyrimethamine, 29 quinine, 26 quinine plus tetracycline, 18,19 chloroquine plus sulphadoxine-pyrimethamine, 27 and chlorproguanil-dapsone. 31 The therapeutic regimens for both studies on vivax malaria were chloroquine followed by primaquine.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Intervention to Promote Patients' Adherence to Antimalarial Medication: A Systematic Review

Fuangchan

Dhippayom

Kongkaew³

2014

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Non-adherence as a major contributor to poor treatment outcomes. This study aimed to explore the effectiveness of existing interventions promoting adherence to antimalarial drugs by systematic review. The following databases were used to identify potential articles: MEDLINE, EMBASE, the Cochrane CENTRAL, and CINAHL (through March 2013). From 1,813 potential papers identified, 16 studies met the selection criteria comprising 9,247 patients. Interventions were classified as packaging aids, visual media, combined visual media and verbal information, community education, medication supervision, and convenient regimen. These interventions were shown to increase adherence to antimalarial drugs (median relative risk = 1.4, interquartile range 1.2-2.0). Although a most effective intervention did not emerge, community education and visual media/verbal information combinations may well have most potential to improve adherence to antimalarial medication. These interventions should be implemented in combination to optimize their beneficial effects. The current understanding on improved adherence would facilitate to contain outbreaks of malaria cost effectively.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Intervention to Promote Patients' Adherence to Antimalarial Medication: A Systematic Review

Fuangchan

Dhippayom

Kongkaew³

2014

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…It has been proven that efficacy of artemether/lumefantrine for the treatment of uncomplicated falciparum malaria in Bangladesh is still high 14 . As emergence and spreading drug resistence is a serious problem wordwide puts on pressure for constant change of drug policy according to local evidences on sensitivity.…”

Section: Introductionmentioning

confidence: 99%

An open randomized controlled trial to compare the efficacy of two fixed dose combinations of artemesinin based combinations for uncomplicated falciparum malaria in Bangladesh

Samad¹,

Rahman²,

Yunus³

et al. 2014

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

National Malaria Control Program (NMCP) of Bangladesh has introduced Artemisinin Based Combination (ACT), Coartem (R) (Artemether-Lumefantrine (AL), fixed dose combination, in the confirmed cases of uncomplicated P. falciparum malaria since 2004. Despite the reduction of mortality due to malaria, the development and spread of anti-malarial drug resistance wordwide posing a threat to the health services and will make it difficult to control malaria in Bangladesh in future. We need to have an alternative to Coartem which could be Artesunate-amodiaquine (AA) in a fixed dose combination (FDC), a cheaper altenative not yet evidenced to be effective and safe to our population. In this study we compared the efficacy and safety of Artemether + Lumefantrene (FDC, Coartem®) with Artesunate +Amodiaquine tablets (100/270 mg FDC) for the treatment of uncomplicated P. falciparum malaria in three high risk multi-drug resistant malaria prevalent areas of Bangladesh. It was an open label randomized controlled trial conducted between December 2008 and November 2009 in 4 upazillas in patients over the age 12 to 60 years diagnosed as a case of uncomplicated P.falciparum malaria. The outcome of the cases were measured as clinical response, parasitological response, defervescence time and parasite clearance time. Drug safety was assessed by comparing the adverse events. A total of 252 cases were randomized to receive Artesunate + Amodiaquine (AA group, 147 cases) and Artemether + Lumefantrene (AL group, 106 cases), one lost to follow up at day 28 in AA group. The distribution of the cases was comparable by age, sex and study sites. Treatment success' response was observed 100% in the AL group and AA group had 99%, two failures with AA were late treatment failures and the difference was not statistically significant (p>.1). The parasitological sensitive (S) response was observed in 97% of cases in AL group and 95% in the AA group, and was not a statistically significant difference. There was no significant difference in deffervescence time and parasite clearance time between two groups of cases. No serious adverse events were observed. The frequencies of minor adverse events were insignificantly different between the two treatment groups. The two ACT regimen, AA and AL had no significant difference in efficacy and safety for treatment of Uncomplicated Malaria in Bangladesh. However, there were few more failures with AA regimen compared to AL regimen, which was not statistically significant. Both these regimens can be used alternatively by the NMCP of Bangladesh as first-line treatment option.

show abstract

Medication adherence framework: A population‐based pharmacokinetic approach and its application in antimalarial treatment assessments

Ding,

Hoglund,

Tarning

2024

CPT Pharmacom & Syst Pharma

View full text Add to dashboard Cite

We reported here on the development of a pharmacometric framework to assess patient adherence, by using two population‐based approaches – the percentile and the Bayesian method. Three different dosing strategies were investigated in patients prescribed a total of three doses; (1) non‐observed therapy, (2) directly observed administration of the first dose, and (3) directly observed administration of the first two doses. The percentile approach used population‐based simulations to derive optimal concentration percentile cutoff values from the distribution of simulated drug concentrations at a specific time. This was done for each adherence scenario and compared to full adherence. The Bayesian approach calculated the posterior probability of each adherence scenario at a given drug concentration. The predictive performance (i.e., Youden index, receiver operating characteristic [ROC] curve) of both approaches were highly influenced by sample collection time (early was better) and interindividual variability (smaller was better). The complexity of the structural model and the half‐life had a minimal impact on the predictive performance of these methods. The impact of the assay limitation (LOQ) on the predictive performance was relatively small if the fraction of LOQ data was less than 20%. Overall, the percentile method performed similar or better for adherence predictions compared to the Bayesian approach, with the latter showing slightly better results when investigating the adherence to the last dose only. The percentile approach showed acceptable adherence predictions (area under ROC curve > 0.74) when sampling the antimalarial drugs piperaquine at day 7 postdose and lumefantrine at day 3 postdose (i.e., 12 h after the last dose). This could be a highly useful approach when evaluating programmatic implementations of preventive and curative antimalarial treatment programs in endemic areas.

show abstract

Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial

Cited by 52 publications

References 11 publications

Intervention to Promote Patients' Adherence to Antimalarial Medication: A Systematic Review

Intervention to Promote Patients' Adherence to Antimalarial Medication: A Systematic Review

An open randomized controlled trial to compare the efficacy of two fixed dose combinations of artemesinin based combinations for uncomplicated falciparum malaria in Bangladesh

Medication adherence framework: A population‐based pharmacokinetic approach and its application in antimalarial treatment assessments

Contact Info

Product

Resources

About